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Colonic carcinoma is one of the most common internal malignancies and is the second leading cause 
of deaths in United States. Methotrexate (MTX) is a drug of choice in the treatment of colon cancer. 
The aim of the present research work was to develop and characterize colon targeted pellets of MTX 
for treatment of colonic carcinoma. The product and process parameters were optimized by screening 
methods. Pellets were prepared by extrusion spheronization using microcrystalline cellulose (MCC) as 
spheronizing aid and ethyl cellulose (EC) as release retardant in different ratio. Based on the physical 
appearance, sphericity and % in vitro drug release, batch P17 containing EC: MCC (3:7) was optimized 
for core pellets. The site specificity was obtained by screening the coating polymers and by coating 
the core pellets with EudragitS100. The 32 full factorial design was applied in which airflow rate (X1) 
and coating time (X2) were the independent parameters and physical appearance (Y1) and time taken 
for 100% drug release (Y2) were selected as the dependent variables. From the results obtained, 6min 
of coating time and 60cm3/min airflow rate was optimized. The batch B5 showed appropriate physical 
appearance and % in vitro drug release upto 17hr indicating sustained release property. The ex-vivo 
studies performed on rat colon indicated a significant relation with the in vitro drug release. The drug 
release followed Higuchi’s model indicating the diffusion pattern of drug release from the matrix of 
pellets. Thus, the coated pellets can be a good candidate for site specific delivery of MTX to colon by 
decreasing the gastric irritation and thus to improve bioavailability.
Keywords: Ethyl cellulose. Microcrystalline cellulose. Eudragit S100. Extrusion-spheronization. 
Modified fluid bed coater. Ex-vivo drug release study.
INTRODUCTION
Colon cancer is a cancer from uncontrolled cell 
growth in the colon. Colon cancer cells invade and damage 
healthy tissue in the nearby region. Chemotherapy is used 
for the treatment of colonic carcinoma. Conventional 
chemotherapy is not effective in colonic carcinoma as the 
drug normally dissolves and absorbs in the stomach and 
small intestine and does not reach the target site in effective 
concentration. Thus, effective treatment demands site 
specific targeting of the drug for more effective treatment. 
Methotrexate (MTX) is an antineoplastic, folate 
antimetabolite with immunosuppressant properties 
which is used as the drug of choice in the treatment of 
colonic carcinoma. It is an inhibitor of tetrahydrofolate 
dehydrogenase  and prevents  the  format ion  of 
tetrahydrofolate, necessary for synthesis of thymidylate, an 
essential component of DNA. Methotrexate is used in the 
treatment of certain neoplastic diseases, severe psoriasis, 
and adult rheumatoid arthritis and in autoimmune diseases 
such as Crohn’s disease, etc. Lynch syndrome, often called 
hereditary nonpolyposis colorectal cancer, is a type of 
inherited cancer of the digestive tract, particularly the 
colon and the rectum. The 40% of lynch syndrome related 
colorectal cancers are caused by inherited mutations in the 
MSH2 gene. Methotrexate selectively destroys the cells 
lacking the MSH2 gene function and it is the excellent 
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treatment for patients with genetic alteration (Sogali, 
Yousuff, Nayak, 2012).
It is possible to deliver MTX to the inner surface 
of the colon that destroys small tumours which arise 
spontaneously in this region by the development of pH 
dependent system. The even drug distribution through 
colon is possible by multiparticulate system. The enteric 
coated pellets cover the entire region of colon and resist 
the release of the drug in stomach and small intestine and 
thereby preventing the irritation in the stomach. Thus, the 
aim of the present work was to formulate and evaluate 
delayed release colon targeted pellets of MTX for the 
treatment of colonic carcinoma by decreasing the gastric 
irritation, reducing dose frequency and to improve patient 
compliance.
MATERIAL AND METHODS
Methotrexate (Sun Pharmaceutical Pvt. Ltd, 
Baroda, Gujarat), Eudragit S100 and Eudragit RS30D 
(Rohm Pharma, GmbH, Germany) and Chitosan 
(Chitoclear FG95) (Primex, Norway) were obtained 
as gift samples. Microcrystaline cellulose (Avicel 
PH101), pectin and carragenan were procured from 
FMC Biopolymer, USA and Himedia, India respectively. 
Ethyl cellulose was obtained from Loba Chemie, India. 
All ingredients and reagents used were of analytical or 
equivalent grade.
Formulation development of Methotrexate core 
pellets
Pre-formulation Studies
Selection of excipients 
The excipients were selected based on the literature 
review (Sogali, Yousuff, Nayak, 2012; Vervaet, Baert, 
Remon, 1995; Steckel, Mindermann-Nogly, 2004; Priese, 
Frisch, Wolf, 2015). Pectin, carrargenen, chitosan, ethyl 
cellulose as release retardants and microcrystalline 
cellulose (MCC) (Avicel PH 101) as the spheronizing aid 
were selected for the preformulation studies.
Method of preparation of core pellets (Gupta et al., 
2011)
The pellets were prepared by pelletization technique 
using extrusion/spheronization. All excipients were passed 
through sieve No. 40 prior to pelletization and then they 
were mixed uniformLy in a mortar and pestle. Granulating 
fluid was added dropwise to the mixture to obtain damp 
mass which was then extruded using a screw extruder. The 
extrudates were immediately spheronized and the pellets 
were dried in fluid bed dryer. 
Screening of polymers (Sogali, Yousuff, Nayak, 2012; 
Steckel, Mindermann-Nogly, 2004)
The formation of pellets using different polymers 
and their concentration was taken into account. The 
batches were prepared by taking ratio of 1:9 to 9:1 of 
polymer: MCC. The polymer was selected depending 
on the physical appearance considering whether pellets 
were formed or not and its sphericity. The batches were 
prepared without incorporation of drug. The polymer 
which formed pellets with appropriate sphericity and 
physical appearance was selected for further study.
Determination of the granulating fluid and its 
amount
The isopropyl alcohol (IPA) and water were selected 
as the granulating fluids on the basis of literature review 
(Hileman, Upadrashta, Neau, 1997). The granulating 
fluid was added in batches P1 (IPA) and P2 (water) till 
it formed the proper pellets by keeping all the other 
product parameters constant. The amount of the selected 
granulating fluid was varied and depending upon the 
formation of pellets and the physical appearance, the 
optimum amount of granulating fluid was determined. 
Optimization of process variables 
Various process variables like spheronization 
speed, spheronization time and drying time were 
optimized by formulation of different batches as per 
Table I. The fixed ratio of Ethyl cellulose: MCC were 
used for preparation of pellets for the optimization. 
Drug was not incorporated in these batches and the other 
parameters were kept constant. 
Formulation of Methotrexate core pellets
Based on the results of the preformulation studies 
including selection and the optimization of the product 
and process parameters, the different batches P15-P23 
containing ethyl cellulose: MCC (1:9 to 9:1) were 
formulated with the incorporation of Methotrexate as 
a drug. The selection of the optimized batch of core 
pellets was performed based on the results of formation 
of pellets, physical appearance, sphericity, micromeritic 
parameters,% drug loading and the% drug release.
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Evaluation of Methotrexate core pellets (Steckel, 
Mindermann-Nogly, 2004; Gupta et al., 2011; Akhgari, 
Sadeghi, Garekani, 2006; Kaynak, Kas, Oner, 2007; He 
et al., 2008; Sriamornsak et al., 2008)
Micromeretic parameters 
The micromeretic parameters of the uncoated 
pellets comprised the angle of repose, bulk density, tapped 
density, Compressibility Index and Hausner’s ratio. 
Angle of repose (θ) 
It is used to estimate the flow property of pellets. The 
angle of repose of pellets was determined by the funnel 
method. The accurately weighed pellets were taken in 
the funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel remains 2 cm above the 
base. The pellets were allowed to flow through the funnel 
freely on to the surface. The diameter of the pellet cone 
was measured and angle of repose was calculated using 
the following equation.
  (1)
where h = Height (cm), r = Radius (cm) of the pellet cone.
Bulk density 
Apparent bulk density was determined by pouring 
the pellets into a graduated cylinder. The bulk volume and 
weight of the pellets was determined. The bulk density was 
calculated using following equation,
  (2)
where, 𝜌𝑏 = Bulk density (gm/cm3), M = Weight of pellets 
(gm), Vb = Bulk volume (mL)
Tapped density 
The measuring cylinder containing a known mass 
of pellets was tapped for 100 times. The minimum 
volume occupied in the cylinder and weight of the pellets 
was measured. The tapped density was calculated using 
following equation,
  (3)
where, 𝜌𝑡 = Tapped density (gm. /cm3), M = Weight of 
pellets (gm.), Vt = Tapped volume (mL)
Hausner’s ratio 
The Hausner’s ratio is used for the estimation of 
the flow property of pellets. Hausner’s ratio is the ratio 
of tapped density to bulk density of pellets. Its value 
less than 1.25 indicates excellent flow of particles and 
value more than 1.25 indicates poor flow property. The 
Hausner’s ratio of the granules was determined by the 
equation,
  (4)
Moisture content 
During extrusion, three samples of about 8–10 gm 
were taken and dried at 75 °C over 36 hr in a hot air oven. 
The moisture content (Mc) (%) was calculated according 
to the equation, where md is the dried mass and mw is the 
wet mass:
 Mc = (mw-md)/ md * 100 (5)
Sphericity index
In order to determine the sphericity of the pellets, the 
pellets were taken on a slide. The slide was placed on the 
stage of the microscope and the images and the circulatory 
parameters were determined. This parameter was checked 
TABLE I - Optimization of various process variables for pellet formulation
Batch no. P6 P7 P8 P9 P10 P11 P12 P13 P14
Spheronization speed 1000 rpm 1150 rpm 1350 rpm 1150 rpm 1150 rpm 1150 rpm 1150 rpm 1150 rpm 1150 rpm
Spheronization time
Till pellets 
were 
formed 
Till pellets 
were 
formed 
Till pellets 
were 
formed 
3 min 6 min 9 min 6 min 6 min 6 min
Drying time Till pellets were dried 
Till pellets 
were dried
Till pellets 
were dried 
Till pellets 
were dried
Till pellets 
were dried
Till pellets 
were dried 2 min 3 min 4 min
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by taking 100 pellet particles. The sphericity index was 
calculated using the equation;
 S = p2 / (12.56 X A) (6)
where, A is the area (cm2) and p is the perimeter (cm)
Drug content 
Equivalent weight to 2.5 mg of methotrexate 
pellets was dissolved in 50 mL of 0.1 N HCl. The drug 
concentration in 0.1 N HCl with proper dilution was 
analyzed spectrophotometrically by UV spectrophotometer 
at 306 nm.
Friability 
Friability of all pellets was determined by USP 
friability test. Friability of the pellet formulations was 
evaluated over 10 g of samples in Roche Friabilator at 25 
rpm for 4 min. Prior to and following the test, the weights 
of the formulations were accurately recorded and the 
friability ratios were calculated with Equation no. 7. The 
results were expressed in terms of the percentage of weight 
lost during the process.
 F= (W1-W2)/W1 * 100 (7)
where, W1 is the initial weight, W2 is the final weight of 
the formulation.
In vitro drug release studies of uncoated pellets 
(Gupta et al., 2011)
The release of drug from the developed formulations 
in the environment of colon was determined using USP 
XXIII dissolution apparatus I. Pellets were placed in the 
basket, which was further immersed in beaker containing 
900 mL of phosphate buffer pH 7.4 as dissolution media 
maintained at 37 ± 0.5 °C and 50 rpm. Aliquots of 5 
mL were withdrawn every 15 min for first hr, 30 min 
for second hr and then every hour until 100% drug 
release was obtained, with the replacement of 5 mL of 
the fresh medium. Correction factors for each aliquot 
were considered in calculation of drug release profile. 
Absorbance of sample after proper dilution was measured 
at 303 nm using U.V. spectrophotometer against blank. 
Concentration of drug was determined from the standard 
plots of the drug in phosphate buffer pH 7.4 previously 
calculated and the% drug release was calculated at each 
sampling time. The study was performed in triplicates.
Formulation of enteric coated Methotrexate 
pellets 
The optimized batch of core pellets was selected for 
the coating. The pellet cores were coated in a fabricated 
fluidized bed coater (Figure 1). The air flow rate and the 
coating time were controlled and the pellets were dried 
in the fluid bed dryer which were then evaluated for 
measurement of the physical characteristics.
Screening of coating polymer and its amount 
(Akhgari, Sadeghi, Garekani, 2006; Kaynak, Kas, Oner, 
2007; He et al., 2008)
Based on the literature review, coating polymers 
were selected. Eudragit FS30D (ready to use dispersion) 
and Eudragit S100 were dissolved in organic solvent 
(IPA: Acetone) and then PEG 6000 as plasticizer and talc 
were added to prepare the coating solution. The pellets of 
batch C1 (Eudragit FS30D) and C2 (Eudragit S100) were 
coated to select the appropriate coating polymer formed 
by fabricated fluid bed coater to obtain good coating 
uniformity. The amount of coating polymer was varied 
in batch C3, C4 and C5 (Table II) and the selection was 
done based on the physical appearance and the coating 
consistency of the pellets.
Determination of coating bed temperature
The temperature at which the pellets are dried during 
and after coating process is the important parameter for 
the coated pellets. The pellets of batches C6-C8 were 
dried at different temperatures (Table II). The selection 
was performed on the basis of whether the pellets got 
dried at that particular temperature or not and the physical 
appearance that includes the coating consistency and 
drying of the film coat.
FIGURE 1 - Fabricated fluid bed coater.
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Optimization of enteric coated methotrexate 
pellets 
The 32 full factorial design was applied using Design 
Expert® 9.0.1.0 (Stat-Ease. Inc. Minneapolis, USA) 
software for the optimization of coated pellets. The air 
flow rate (X1) and the coating time (X2) were selected as 
independent variables and Physical characteristics such 
as properly coated pellets with no aggregates (Y1) and 
time required for 100% Drug release (Y2) were selected 
as the dependent variables (Table III). Results obtained 
were statistically analysed at 5% level of significance. 
A check point analysis was performed to confirm the 
role of derived polynomial equation and contour plots 
in predicting the responses in the coating of the pellet 
formulation. Coating was performed experimentally at 2 
points and then evaluated for the responses. Differences 
of theoretically computed values of dependent variables 
and experimentally obtained values of dependent variables 
were checked by using t test. The desirability function was 
also applied to the responses.
Evaluation of methotrexate coated pellets
The different batches of Methotrexate coated pellets 
(Batches B1-B9) were evaluated by all the parameters as 
that of the uncoated pellets.
In-vitro drug release studies of coated pellets 
(Gandhi, Kaul, Panchagnula, 1999; Gupta et al., 2011)
The release of drug from the developed formulations 
in the environment of gastrointestinal tract was determined 
by USP XXIII dissolution apparatus I. Pellets were placed 
in the basket, which was further immersed in beaker 
containing 900 mL of dissolution media maintained at 37 
± 0.5 °C and 50 rpm. For cumulative drug release studies, 
dissolution media consisted of 0.1 N HCl was kept for 
2 h, which was further placed in phosphate buffer pH 
6.8 for 4 h and then in phosphate buffer pH 7.4 for 16 h. 
Aliquot samples of 5 mL were withdrawn every 15 min 
for first hour, 30 min for second hour and then every hour 
up to 16 h with replacement of 5 mL of the fresh medium. 
Correction factors for each aliquot were considered in 
the calculation of release profile. Absorbance of sample 
after proper dilution was measured at 303 nm using 
U.V. spectrophotometer against blank. Concentration 
of drug was determined from the standard plots of the 
drug in phosphate buffer pH 7.4 previously calculated 
and the%drug release was calculated at each sampling 
time. The study was performed in triplicates. To study the 
release mechanism of the pellets formulation, the release 
data were fitted to the different kinetics models.
Ex-vivo study (He et al., 2008)
Male Albino Wister rats were used for the 
pharmacokinetic study (Protocol No. RPCP/IAEC/2013-
2014/MPH-PT-42). The rat was kept in the fasted condition 
over night. It was then sacrificed and the colon along with 
its contents was isolated. The lower end was closed by using 
thread or clip while from the upper end pellets equivalent to 
unit dose were placed and the upper end was also tied. The 
whole tissue was then placed in the assembly containing 
phosphate buffer pH 7.4 and continuous air supply was 
provided with the maintenance of temperature. Samples 
were withdrawn at every hour and analysis was performed 
by UV spectrophotometer at 303 nm.
TABLE II - Optimization of coating variables of methotrexate core pellets
Batch no. C3 C4 C5 C6 C7 C8
Amount of coating solution (mL) 5 7 9 7 7 7
Coating bed temperature (°C) Till it dried Till it dried Till it dried 50 60 70
TABLE III - 32 full factorial design for methotrexate coated pellets
Factors 
(Independent variables)
Levels Used Responses 
(Dependent variables)-1 0 1
X1=Air Flow rate (cm3/min) 40 60 80 Y1=Physical characteristics*
X2=Coating time (min) 4 6 8 Y2=%Drug release
*Physical appearance: 1- Aggregated pellets, 2- Average coating with some aggregated pellets, 3- Properly coated pellets with no 
aggregates
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RESULTS AND DISCUSSION
Formulation development of methotrexate core 
pellets
Pre-formulation studies
Screening of polymers 
During screening of polymers, the pellets were 
not formed in any ratio from1:9 to 9:1 (Pectin: MCC). 
This might be due to the fact that pectin imbibed a lot of 
water and did not break up to form pellets. In the batches 
containing carrageenan, the pellets were formed in ratio 
1:9 to 4:6 (carrageenan: MCC) but proper spheres were 
not formed; they formed rough surface and uneven shaped 
pellets whereas in other ratios pellets were not formed. 
In the batches containing chitosan, proper even shaped 
pellets were formed with consistent sphericity in ratios 1:9 
to 5:5 (chitosan: MCC) but pellets got immediately easily 
disintegrated because chitosan acted as pore forming agent 
(Omwancha et al., 2013). Therefore, pellets with higher 
concentration of chitosan were not prepared. This might 
be due to weak ionic bond between chitosan and MTX 
(Gupta et al., 2011; Steckel, Mindermann-Nogly, 2004) 
and thus it was not continued for the further study. In the 
batches containing ethyl cellulose, pellets were properly 
formed in ratio 1:9 to 5:5. Based on the results, it was 
concluded that ethyl cellulose forms appropriate pellets 
and so it was selected as appropriate release retardant for 
the pellet preparation (He et al., 2008). Out of all these 
batches, randomLy ratio 2:8 (ethyl cellulose: MCC) was 
selected for the optimization of the other parameters.
Determination of the granulating fluid and its 
amount
From the results, it was concluded that when 
isopropyl alcohol was used as granulating fluid, no binding 
took place. The addition of high amount of the fluid lead 
to formation of a partially damp mass which again turned 
into powder upon extrusion due to its volatile nature. 
In case of water, appropriate binding occurred as the 
water molecules properly get adsorbed onto the surface 
and so upon extrusion, appropriate extrudates were 
formed. In addition, non-volatile nature of water helps 
in retaining the sphericity upon spheronization (Vervaet, 
Baert, Remon, 1995). Therefore, water was selected as the 
appropriate granulating liquid. From various trials, 12 mL, 
14 mL and 16 mL of the granulating fluid were selected as 
the optimum range. In batch P3 (12 mL), the damp mass 
formed was comparatively dry and upon extrusion only 
very few amount of the extrudates were formed and upon 
spheronization they remained as extrudates, due to lack 
of moisture. In batch P4 (14 mL) of water, proper damp 
mass was formed and also the extrudates were properly 
formed. When these extrudates were spheronized, they 
lead to the formation of proper pellets with appropriate 
sphericity. In batch P5 (16 mL) of water, highly damp mass 
was formed and extrudates tend to aggregate and stick to 
each other upon extrusion and when these extrudates were 
spheronized, it lead to the formation of dumbled shaped 
pellets. Thus, batch P4 containing 14 mL of granulating 
fluid was considered as optimum for the further study.
Optimization of the process parameters (Vervaet, 
Baert, Remon, 1995; Gandhi, Kaul, Panchagnula, 
1999)
The optimization of the process variables was 
performed by selecting the P4 batch. The process 
parameters like extrusion speed, extrusion time, 
spheronization time, spheronization speed and drying 
time were selected. The extrusion speed and extrusion time 
did not have considerable effect on the pellet properties 
so they were fixed. 
Spheronization speed
The spheronization speed is a critical parameter for 
pellet formulation (Vervaet, Baert, Remon, 1995). In the 
batch P6, the extrudates were spheronized at 1000 rpm 
till it formed pellets. The pellets formed were more of 
rod and dumbled shaped and upon increasing time, the 
pellet got dried and so they did not turn into appropriate 
spheres. This can be due to the fact that the extrudates got 
partially dried and so they remained rods even after high 
time of spheronization. Batch P7 was spheronized at 1150 
rpm till the pellets were formed. The extrudates properly 
got converted to pellets and perfect spheres were formed. 
In batch P8, the extrudates were spheronized at 1350 
rpm till they formed pellets but there was wide range of 
particle size variation and an increased amount of fines. 
Therefore, batch P7 prepared with 1150 rpm was selected 
as the optimum batch.
Spheronization time
Spheronization time is also an important parameter 
as lower and higher spheronization time leads to 
aggregation of particles which do not retain their sphericity 
upon drying (Vervaet, Baert, Remon, 1995). In batch P9 
(3 min), pellets were formed but the sphericity was not 
obtained. The pellets formed were partially dumbled and 
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rod shaped. The batch P10 (6 min) exhibited pellets with 
proper sphericity while in batch P11 (9 min), the pellets 
were formed but they tend to re-aggregate. Also upon 
drying, there was a large variation in size distribution and 
increased amount of fines. Thus, 6 min spheronization time 
was selected for the preparation of spherical pellets with 
least amount of fines during further study.
Drying time
Proper drying is required for the perfect pellet 
formation as moisture content may lead to fungal growth 
and excess of drying may lead to blackening of pellets 
(Akhgari, Sadeghi, Garekani, 2006). 
In the batch P12 with 2 min of drying time, the 
pellets did not dry properly as they tend to aggregate due 
to high moisture content. In batch P13, the drying of the 
pellets was appropriate while in the batch P14 having 
drying time of 9 min, over drying took place. So batch P13 
with drying time of 6 min was selected for further study.
Evaluation parameters of the methotrexate core 
pellets (Akhgari, Sadeghi, Garekani, 2006; Steckel, 
Mindermann-Nogly, 2004; Kaynak, Kas, Oner, 2007; 
Gandhi, Kaul, Panchagnhla, 1999; Gupta et al., 2011)
During the formulation of batches P15-P23, in the 
batches P20-P23, the pellets were not formed. It led to 
formation of the white spots on the pellet surface with 
more of dumble shaped pellets. This can be attributed 
to the uneven distribution of ethyl cellulose and a 
considerable decrease in the spheronizing aid, MCC 
(Akhgari, Sadeghi, Garekani, 2006) (Table IV). From 
table V, it was concluded that batch P17 had good flow 
property as compared to other batches. The batches P15 
to P19 exhibited sphericity index ranging from 0.9967 
to 0.9980. The ideal sphericity index of pellets should 
be near to 1. Thus the sphericity index value near to 
1 indicated that the prepared pellets exhibited proper 
sphericity and retained their structure with narrow size 
distribution (Figure 2). The moisture content helps to 
determine the presence of water in the extrudates as well 
as the pellets. Friability determines the strength of the 
pellets while the drug loading determines the amount of 
the drug present in the pellets (Kaynak, Kas, Oner, 2007; 
Jia et al., 2011). From the results, it was concluded that 
there was no specific marked difference in the values 
of each parameter. All the physical parameters were 
satisfactory of batches P15-P19 of ethyl cellulose and so 
the drug release study was carried out in those batches 
only. In batches P15-P19, the batch P17 exhibited 100% 
drug release at 14th hour which was found to be highest 
as compared to other batches. So batch P17 was selected 
the optimized batch (Figure 3). Thus, it can be concluded 
that as the polymer concentration increases, there is an 
increase in the sustain action of drug release. Though it 
TABLE IV - Evaluation of the methotrexate core pellets
Batch no. P15 P16 P17 P18 P19 P20 P21 P22 P23
Ethyl cellulose : MCC 1:9 2:8 3:7 4:6 5:5 6:4 7:3 8:2 9:1
Pellets formed Yes Yes Yes Yes Yes No No No No
Sphericity obtained Yes Yes Yes Yes Yes No No No No
100% drug release 11 h 12 h 14 h 12 h 11 h - - - -
TABLE V - Evaluation parameters of the methotrexate core pellets
Evaluation Parameters P15 P16 P17 P18 P19
Bulk Density (g/mL) 0.628 ±0.09 0.634 ±0.07 0.627 ±0.01 0.659 ±0.03 0.631±0.06
Tapped density(g/mL) 0.729 ±0.05 0.741 ±0.06 0.727 ±0.02 0.762 ±0.03 0.734 ±0.05
Hausner’s Ratio 1.16±0.03 1.16±0.02 1.15±0.01 1.15±0.03 1.16±0.05
Angle Of Repose (θ) 31.21±0.06 30.14±0.04 28.83±0.02 31.27±0.03 31.15±0.03
Moisture content of extrudates (%) 4.98±0.09 3.54±0.07 3.63±0.03 3.87±0.03 3.98±0.08
% Moisture content of pellets 0.043±0.02 0.049±0.01 0.041±0.01 0.047±0.02 0.047±0.04
% Friability 0.421±0.02 0.418±0.03 0.415±0.01 0.435±0.04 0.513±0.03
% drug loading 99.53±0.02 99.59±0.03 99.62±0.01 99.52±0.04 99.60±0.03
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was noticed that above the optimum concentration, the 
sustained action was decreased (He et al., 2008). 
Thus, the batch P17 with ethyl cellulose: MCC (3:7) 
ratio was selected as the optimized batch of core pellets 
and it was used further for coating of the pellets.
Formulation of enteric coated methotrexate 
pellets 
Optimization of coating parameters
Screening of coating polymer
From the literature review and from the study 
of colonic pH, Eudragit FS30D (30% dispersion) and 
Eudragit S100 were selected as the coating polymer for 
targeting the delivery of pellets to colonic site. In the batch 
C1 containing Eudragit FS30D, the improper coating was 
observed. The formed pellets got aggregated and proper 
coating film was not developed over pellets. 
While in batch C2 containing Eudragit S100, even 
coating with flexible smooth surface was observed upon 
drying. Thus from the results, it was concluded that 
Eudragit S100 solution was optimum as it exhibited 
appropriate strength and flexibility to the pellet coat. This 
might be due to the fact that Eudragit S100 enables even 
coat and dries easily due to the presence of the organic 
solvents like acetone and iso-propyl alcohol (Akhgari 
et al., 2006) while Eudragit FS30D being an aqueous 
dispersion does not get dried easily and even small amount 
of it leads to aggregation of the pellet particles. 
Determination of amount of coating polymer
Appropriate amount of coating solution is required 
for proper coating of pellets. In the batch C3 (5 mL), the 
coating was uniform visually but under the microscope, 
large patches of uneven coat were observed. In the batch 
C4 (7 mL), coating was proper and the release of drug 
occurred only after coming in contact with colonic fluid. 
The batch C5 (9 mL) exhibited proper coating but the 
drug release was sustained at a greater extent such that 
the drug was not released up to 2 h even at colonic pH. 
Thus, the batch C4 was selected for further study (Table 
VI).
Determination of coating bed temperature
The coating bed temperature is the temperature at 
which the pellets get heated in the fabricated fluidized 
bed coater. In the batch C6, the pellets coated at 50 0C 
remained sticky which indicates too less temperature to 
dry the pellet while batch C7 prepared at 600C exhibited 
proper drying of the coating film. In the batch C8, the 
polymer got melted during coating and hard aggregates 
were formed on cooling which might be due to higher 
temperature of the bed of coater (70 0C). Thus, batch C7 
having 60 0C was considered as appropriate temperature 
for the coating process (Table VI). 
Statistical analysis by 32 full factorial design
32 full  factorial design was applied for the 
optimization of methotrexate coated pellets. The results 
of the effect of the independent variables on dependent 
variables are given in following full model polynomial 
equation (equation 8 and 9).
Effect on time required for 100% drug release:
FIGURE 3 - % Cumulative drug release of methotrexate core 
pellets.
FIGURE 2 - Images of optimized batch (P17) of methotrexate 
core pellets.
TABLE VI - Optimization of the coating variables
Batch no. C3 C4 C5 C6 C7 C8
Amount of coating solution (mL) 5 7 9 7 7 7
Coating bed temperature (°C) Till it dried Till it dried Till it dried 50 60 70
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Y1= 16.78 + 0.33*X1 (p=0.04634) –0.17*X2 (p=0.7316) 
+ 0.25*X1X2 (p=0.03741) +0.67*X12 (p=0.0468) + 
2.17*X22 (p=0.00598)  (8)
Effect on physical appearance:
Y2= 2.67 – 4.93*X1 (p=0.0583) + 0.78*X2 (p=0.6608) 
+ 6.25*X1X2 (p=0.04956) –0.167 *X12 (p=0.0234) - 
6.12*X22 (p=0.3982)  (9)
The term of full model polynomial equation having 
insignificant p value (p>0.05) have negligible contribution 
to obtain dependent variables and thus are omitted to get 
reduced model equation.
The equation 10 and 11 representing the quantitative 
effect of the formulation variable on the Particle size and% 
cumulative drug release are describe below:
Y1= 16.78 + 0.33*X1 + 0.25*X1X2 +0.67*X12 +  
2.17*X22  (10)
Y2=2.67 – 4.93*X1+ 6.25*X1X2 –0.167 *X12 (11)
Response surface graphs were generated using above 
polynomial equations, which represents simultaneous 
effect of one variable on response parameters by taking 
one variable at a constant level.
The P value (5% level) and the value of correlation 
coefficient (r2) obtained for effect on physical appearance 
was 0.0050 and 0.9119 indicating a good fit of the model. 
The counter plot for the effect on physical appearance 
(Figure 4 (A)) shows that the red zone having number 3 
is the zone where best results will be obtained then the air 
flow is 60 and the coating time is 4 min. Moreover, the 3D 
response surface plot (Figure 4 (B)) suggests that as the 
coating time increases up to certain extent, good physical 
appearance was observed. The increase in air flow rate 
leads to improper physical appearance. Both the combined 
effect of air flow rate and coating time leads to positive 
effect on physical appearance. 
The P value (5% level) and the value of correlation 
coefficient (r2) obtained for effect on time taken for 100% 
drug release was 0.00381 and 0.9021 indicating a good 
fit of the model. The counter plot for time taken for 100% 
drug release (Figure 5 (A)) shows that the green zone 
having centre spot is the zone where best results will be 
obtained then the air flow is 60 and the coating time is 4 
min. The 3D response surface plot (Figure 5 (B)) suggests 
that as the coating time increases up to certain extent, 
leads to increase in time taken for 100% drug release. 
The increase in air flow rate up to certain extent leads to 
an increase in the time taken for 100% drug release. It can 
be concluded that the air flow rate (X1) has positive effect 
on time taken for 100% drug release. While coating time 
(X2) does not show much effect on it. Both the combined 
effect of air flow rate and coating time leads to positive 
effect on physical appearance and the time taken for 100% 
drug release. In order to validate the equation that describe 
the influence of independent parameters on time taken for 
100% drug release and physical appearance, the additional 
two check point experiments were performed (Table VII) 
. The t-test was also applied between the actual value 
and predicted value of dependent parameters. From the 
results, it was found that there were excellent agreement 
between the measured response and predicted response 
by mathematical data. The differences between measured 
and predicted values were not found to be statistically 
significant. 
Thus, it can be concluded that the polynomial 
equations fits the data satisfactorily and were valid for 
predicting the time taken for 100% drug release and 
physical appearance for the enteric coated MTX pellets. 
Thus, considering the results from 32 full factorial design, 
the batch B5 was selected as the optimized batch.
Evaluation of the optimized batch of coated 
methotrexate pellets
The optimized batch B5 was evaluated for various 
parameters like micromeritic parameters, moisture 
FIGURE 4 - (A) Contour plot (B) Response surface 3D plot; indicating the effect of coating time and airflow rate on physical 
appearance.
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content, sphericity index, drug loading and% in-vitro drug 
release study. From the table VIII, it can be concluded that 
the optimized batch B5 exhibited micromeretic parameters 
in the acceptable range. The sphericity index was near to 1 
which indicated appropriate sphericity of the pellets. It can 
also be confirmed by the change in the colour of the pellets 
indicating that they have taken up the coating solution and 
got coated evenly throughout the surface (Figure 6). The 
drug loading was also in the desired range and the drug 
release was sustained up to 17 h which was almost near 
to the complete residence time in colon (Figure 7). Thus, 
it can be concluded that the optimized batch B5 fulfilled 
all the desired criteria. 
Ex-vivo study 
The result of the ex-vivo study indicated that 100% 
drug release was obtained within 24 h as that of the 
residence time for colon. The 71.76% drug release of the 
optimized batch B5 observed during ex-vivo study was 
equivalent to 71.35% drug release during in vitro study 
FIGURE 5 - (A) Contour plot (B) Response surface 3D plot; indicating the effect of coating time and airflow rate on time required 
for 100% drug release.
TABLE VII - Actual and predicted value of physical appearance and time for 100% drug release for check point analysis (n=3)
Batch
Time taken for 100% drug release (h) Physical appearance*
Predicted Actual Predicted Actual 
1 16.53 16 ± 0.12 1.3 1 ± 0.0
2 16.01 16 ± 0.41 1.09 1 ± 0.0
*Physical appearance: 1- Aggregated pellets, 2- Average coating with some aggregated pellets, 3- Properly coated pellets with no 
aggregates
FIGURE 7 - Time taken for 100% drug release for methotrexate 
coated pellets.
FIGURE 6 - Images of methotrexate coated pellets.
TABLE VIII - Results of evaluation parameters of optimized batch 
of methotrexate coated pellets (Batch B5)
Evaluation Parameters Results
Bulk density (g/mL) 0.667±0.09
Tapped density (g/mL) 0.769±0.08
Carr’s Index (%) 13.29±0.07
Hausner’s ratio 1.15±0.06
Angle of repose (θ) 30.73±0.05 ̊
Moisture content (%) 0.058± 0.1
Sphericity index 0.943 ± 0.06
Friability (%) 0.423 ± 0.09
Drug loading (%) 99.58 ± 0.03
Time required for 100% drug 
release (h)
17 ± 0.07 
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at the 10th h. (Figure 8). Moreover, when the drug release 
data were fitted to various kinetic models, it followed 
Higuchi model indicating the diffusion mechanism of the 
drug release from the matrix (Fick’s Law).
CONCLUSION
Colon cancer is the second most common cause 
of mortality in cancer. The chemotherapeutic agent-
Methotrexate is the drug of choice which inhibits the 
thymidylate synthesis and thereby arrests the cell growth 
in S-phase. But, methotrexate gets metabolized in the 
stomach when given orally and does not reach the specific 
site to provide proper treatment. Due to the unwanted 
metabolism, hepatotoxicity and nephrotoxicity are 
prominently seen. The dosing of this drug is thrice a day 
and its half life is 3-4 hrs. Sustained release formulation 
has not been developed yet for methotrexate. Hence, 
the aim of the study was to develop delayed release 
pellets of methotrexate for industrial application, cost 
effectiveness and sustaining the drug release at colonic 
site. The preformulation study was performed in order 
to characterize the purity of the drug and to check drug-
excipients compatibility. Selection of excipients was 
performed thorough literature review and screening 
methods. The results were complied with the standard 
reported values in the literature and revealed that drug and 
excipients were compatible with each other. 
Based on the literature search and wide industrial 
applicability, Extrusion-spheronization was selected to 
prepare pellets. By using Microcrystalline cellulose (MCC) 
(Avicel PH 101) (spheronization aid), Ethyl Cellulose 
(release retardant) and Coating polymer (Eudragit S 100) 
sustained release pellets were developed. The process 
parameters like spheronization speed, spheronization time, 
drying time and the formulation related parameters like 
selection of granulating fluid and its amount, concentration 
of ethyl cellulose were optimized. The effect of different 
formulation parameters and process parameters on physical 
appearance, micromereic parameters, sphericity index, 
friability, drug loading and the% in vitro drug release were 
also studied. Batch P17 with ethyl cellulose: MCC ratio of 
3:7 was obtained as the optimized ratio for the core pellets. 
Based on preliminary study and literature review, coating 
time and coating air flow rate were selected as independent 
variables in 32 full experimental designs as these two 
parameters significantly affect physical appearance and% 
in vitro drug release of pellets. Polynomial equations by 
statistical evaluation of the results were obtained in order 
to correlate the independent and dependent variables. 
Desirability function was utilized to obtain the optimized 
batch. Based on the overall desirability factor and design 
expert software the optimized batch was selected. To 
achieve site specific drug release, fabricated fluid bed 
coater was used to coat all the batches of methotrexate 
pellets using Eudragit S100 as coating polymer. The batch 
B5 containing ethyl cellulse:MCC 3:7 ratio formulated 
with coating time of 6 min and coating air flow of 
60 cm3/mL proved to be optimized batch. The% in vitro 
drug release study was performed by change over media 
in which initially 0.1 N HCl was used followed by 
phosphate buffer pH 6.8 and finally phosphate buffer pH 
7.4 wherein formulation exhibited sustained release effect 
till 17 h. The ex-vivo study was performed in rat colon and 
different kinetic models were applied to check the release 
mechanism of pellets which indicated that coated pellets 
followed Higuchi diffusion mechanism. 
Thus, all the results obtained while development 
of the dosage form were as per the desired set of the 
objectives. Therefore, the coated pellets can be a good 
candidate for site specific delivery of MTX to colon by 
decreasing the gastric irritation, reducing dose frequency 
and by improving patient compliance for the treatment 
of colon cancer. Though, the in-vivo study should be 
performed using suitable animal model to demonstrate 
the enhancement in bioavailability and site specific action 
of formulation. 
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